Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study.

Authors :: VAN DEN REEK, Juul M. P. A.
VAN VUGT, Lieke J.
VAN DOORN°, Martijn B. A.
VAN DER KRAAIJ°, Gayle E.
DE KORT, Wim J. A.
LUCKER, Georges P. H.
HORVATH, Barbara
NJOO, M. David
BOVENSCHEN, H. Jorn
OSSENKOPPELE, Paul M.
DE BRUIN-WELLER, Marjolein S.
DE GROOT, Marjan
MOMMERS, Roland
PREVOO, Ruud L. M. A.
VAN DE KERKHOF, Peter C. M.
SPULS, Phyllis I.
KIEVIT, Wietske
DE JONG, Elke M. G. J.
Source :: Acta Dermato-Venereologica; Jul2018, Vol. 98 Issue 7, p648-654, 7p
Publication Year :: 2018
Abstract: The article offers information about a study which aims to evaluate drug survival of secukinumab in a daily practice psoriasis cohort. Information on the collection of data from several hospitals and the analysis of drug survival using Kaplan– Meier survival curves as well as the treatment of secukinumab, which is the first interleukin-17 inhibitor registered for treatment of plaque psoriasis, is presented.

Subjects :: DRUG efficacy
PSORIASIS
SKIN diseases
CLINICAL trials
COHORT analysis
MEDICAL care

Full Text Access

Tools